Identifying Key Risk Factors for Bell's Palsy and Insights from a Retrospective Analysis

  • Dr. Muhsin Mohammed Al Najim Ministry of Higher Education and Scientific Research, Jabir Ibn Hayyan University for Medical and Pharmaceutical Sciences, Faculty of Medicine, Al-Najaf, Iraq.
  • Lecturer Dr. Hazim Ali Marah Ministry of Higher Education and Scientific Research, College of Medicine, University of Thi-Qar, Thi-Qar, Iraq.
Keywords: Bell's Palsy, House-Brackmann scale, risk factors, CS score

Abstract

A cross-sectional descriptive study was designed, with all patients diagnosed with Bell's palsy in AL-Nasiriya from January 2022 to December 2024 being included in the study. The study population comprised 110 patients. The House-Brackmann scale, a well-established method for the classification of muscle functions, was utilised for the assessment of patient progression. This scale facilitates the evaluation of facial posture both at rest and during voluntary movement, in addition to the identification of any abnormal movements. The scale categorises dysfunction into six distinct degrees or categories, ranging from normal function to severe disability. The classification system utilised in this study is the House-Brackmann scale, a well-established framework for the categorisation of muscle function. This scale has proven to be a valuable tool for the management of patients, as it enables the evaluation of facial posture both at rest and during voluntary movement, in addition to identifying the presence of any atypical movements. The scale delineates six distinct categories or degrees of dysfunction, as outlined below: 1) Grade I: Normal, 2) Grade II: Mild, 3) Grade III: Moderate, 4) Grade IV: Moderately Severe, 5) Grade V: Severe, 6) Grade VI: Total Paralysis. The findings from this study revealed that individuals between the ages of 30 and 39 exhibited a frequency of 40% and a p-value of 33.33%, while those between the ages of 40 and 49 demonstrated a frequency of 44% and a p-value of 36.67%. 0-60 years: frequency 26, p% 21.67, BMI: 25-28: 30, p% 25.00, 29-31: 50, p% 41.67 and >31for 30 patients and p% 25.00, Sex: male: 60, p% 50, Female: 60, p% 50 Affected side: right: 60, p% 54.5. As demonstrated in Table 3, the logistic regression analysis enabled the identification of risk factors and the determination of the most influential factors. The factors that exhibited the greatest influence were identified as the affected side right CS 2.2 OI 1.55-3.6 with a P-value of <0.001 and the left CS 2.23 OI 1.44-3.44 with a P-value of <0.001. The presence of an interval exceeding two years was observed in 3.4% of cases, categorized as CS 3.4. The observed range of OI was 2.4-4.9, with a P-value of <0.001. The designation of Grade IV signifies severe dysfunction in patients. The mean CS score was 4.1, with an observed range of OI 2.7-6.9 and a P-value of <0.001. The designation of Grade V indicates minimal ability, with a mean score of 4.5 and an observed range of 3.8-6.6, both with a P-value of <0.001.

References

Facial nerve palsy and hemifacial spasm. Valls-Solé J. Handb Clin Neurol. 2013; 115:367–380. Doi: 10.1016/B978-0-444-52902-2.00020-5. [DOI] [PubMed] [Google Scholar]

Psychological distress in people with disfigurement from facial palsy. Fu L, Bundy C, Sadiq SA. Eye. 2011; 25:1322–1326. DOI: 10.1038/eye.2011.158. [DOI] [PMC free article] [PubMed] [Google Scholar]

Facial nerve paralysis in children. Ciorba A, Corazzi V, Conz V, Bianchini C, Aimoni C. World J Clin Cases. 2015; 3:973–979. DOI: 10.12998/wjcc. v3.i12.973. [DOI] [PMC free article] [PubMed] [Google Scholar]

Bell's palsy: a review. Singh A, Deshmukh P. Cureus. 2022; 14:0. DOI: 10.7759/cureus.30186. [DOI] [PMC free article] [PubMed] [Google Scholar]

Prevalence, etiology, risk factors, and complications of facial nerve palsy at King Abdulaziz Medical City: a multicenter study. Ragaban A, Alsharif L, Alshaikh NA, et al. Cureus. 2024; 16:0. DOI: 10.7759/cureus.53403. [DOI] [PMC free article] [PubMed] [Google Scholar]

Etiology, diagnosis, and management of facial palsy: 2000 patients at a facial nerve center. Hohman MH, Hadlock TA. Laryngoscope. 2014; 124:0–93. DOI: 10.1002/lary.24542. [DOI] [PubMed] [Google Scholar]

Management of peripheral facial nerve palsy. Finsterer J. Eur Arch Otorhinolaryngol. 2008; 265:743–752. DOI: 10.1007/s00405-008-0646-4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Diagnosis and management of patients with Bell's palsy. Mooney T. Nurs Stand. 2013; 28:44–49. DOI: 10.7748/ns2013.12.28.14.44. e7979. [DOI] [PubMed] [Google Scholar]

Babl, F.E.; Herd, D.; Borland, M.L.; Kochar, A.; Lawton, B.; Hort, J.; West, A.; George, S.; Oakley, E.; Wilson, C.L.; et al. Facial Function in Bell Palsy in a Cohort of Children Randomized to Prednisolone or Placebo 12 Months After Diagnosis. Pediatr. Neurol. 2024, 153, 44–47. [Google Scholar] [CrossRef]

Lee, M.; Mackay, M.; Blackbourn, L.; Babl, F.E. Emotional Impact of Bell’s Palsy in Children. J. Paediatr. Child Health 2014, 50, 245–246. [Google Scholar] [CrossRef] [PubMed]

Yoo, H.W.; Yoon, L.; Kim, H.Y.; Kwak, M.J.; Park, K.H.; Bae, M.H.; Lee, Y.; Nam, S.O.; Kim, Y.M. Comparison of Conservative Therapy and Steroid Therapy for Bell’s Palsy in Children. Korean J. Pediatr. 2018, 61, 332–337. [Google Scholar] [CrossRef] [PubMed]

Wohrer, D.; Moulding, T.; Titomanlio, L.; Lenglart, L. Acute Facial Nerve Palsy in Children: Gold Standard Management. Children 2022, 9, 273. [Google Scholar] [CrossRef]

Somasundara, D.; Sullivan, F. Management of Bell’s Palsy. Aust. Prescr. 2016, 40, 94–96. [Google Scholar] [CrossRef]

Jalaludin, M.A. Methylcobalamin Treatment of Bell’s Palsy. Methods Find. Exp. Clin. Pharmacol. 1995, 17, 539–544. [Google Scholar]

Hamayal, M.; Khurshied, S.; Zahid, M.A.; Khurshid, N.; Shahid, W.; Ali, M.; Ahmed, H.; Nisa, M. Exploring the Significance of Vitamin D Levels as a Biomarker in Ear Diseases: A Narrative Review. Cureus 2024, 16, e54812. [Google Scholar] [CrossRef] [PubMed]

Chabas, J.-F.; Stephan, D.; Marqueste, T.; Garcia, S.; Lavaut, M.-N.; Nguyen, C.; Legre, R.; Khrestchatisky, M.; Decherchi, P.; Feron, F. Cholecalciferol (Vitamin D3) Improves Myelination and Recovery after Nerve Injury. PLoS ONE 2013, 8, e65034. [Google Scholar] [CrossRef]

Ocak, E.; Uyar, M.S.; Kocaoz, D.; Mirici, E.; Acar, A. Role of Vitamin D Deficiency on The Onset and Prognosis of Bell’s Palsy. ENT Updat. 2020, 10, 439–443. [Google Scholar] [CrossRef]

Houlton, J.; Abumaria, N.; Hinkley, S.F.R.; Clarkson, A.N. Therapeutic Potential of Neurotrophins for Repair After Brain Injury: A Helping Hand From Biomaterials. Front. Neurosci. 2019, 13, 790. [Google Scholar] [CrossRef] [PubMed]

Oya, R.; Takenaka, Y.; Imai, T.; Sato, T.; Oshima, K.; Ohta, Y.; Inohara, H. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Hematologic Markers of Bell’s Palsy: A Meta-Analysis. Otol. Neurotol. 2019, 40, 681–687. [Google Scholar] [CrossRef]

Kim, T.H.; Yeo, S.G.; Byun, J.Y. Role of Biomarkers as Prognostic Factors in Acute Peripheral Facial Palsy. Int. J. Mol. Sci. 2021, 23, 307. [Google Scholar] [CrossRef]

Published
2025-02-28
How to Cite
Mohammed Al Najim, D. M., & Ali Marah, L. D. H. (2025). Identifying Key Risk Factors for Bell’s Palsy and Insights from a Retrospective Analysis. Central Asian Journal of Medical and Natural Science, 6(2), 586-593. https://doi.org/10.17605/cajmns.v6i2.2737
Section
Articles